Rochester Clinical Research to more than double their footprint

ROCHESTER, N.Y. (WHEC) — Rochester Clinical Research (RCR) has been at the forefront of COVID-19 studies and trials in our area and now they are expanding.

So far, Rochester Clinical Research has conducted more than 900 clinical trials, involving more than 50,000 study volunteers.

“Well we’ve steadily been growing for the past 27 year’s organic growth up until March 22, we were a 32 person company and since then we’ve grown by over 100%,” president, Adam Larabee said.

Larabee said ever since COVID-19 hit, RCR has been trailblazing making their name even more prominent.

“We’re increasing our space by 150% right now we’re at about 10,000 square feet and we’re using — kind of the era of COVID-19 and the work that it’s brought into us — it’s serving as a catalyst of who we want to become in the future,” Larabee said.

He said that growth prompted demolition for their new clinical and administrative space that began this week.

“With the expansion, it does mean more jobs whether it’s a research assistant, patient care tech, more nurses, more doctors that want to work with us that are under us or in a partnership,” Larabee said.

The move comes as RCR continues to work on several important covid-19 vaccines and a variety of studies including Lyme disease, RSV, flu, migraine relief, smoking cessation, weight loss, CMV and a variety of other pediatric studies.

“Delivering on a COVID-19 vaccine trial means performance and you need to have the people to make that happen so we’ve been constantly hiring people to meet the increase in demand,” Larabee said.

Larabee said this expansion will allow for more medical advancements to take place in Rochester.

“There’s a lot more impact we can have in the community through increased trials, community research, engaging with local area physicians. That means growing our business, growing our headcount so we can deliver more on our core mission of advancing medicine and changing lives,” Larabee said.

Rochester Clinical Research is currently enrolling for several COVID-19 booster studies for ages 18 through 85.

Current trials typically require someone to be fully vaccinated for at least 6 months.

For more information on this trial, click here.